187 related articles for article (PubMed ID: 7866341)
41. Salmeterol, a long acting bronchodilator, in the treatment of asthma.
Morice A
Ir Med J; 1992 Sep; 85(3):82-3. PubMed ID: 1399485
[No Abstract] [Full Text] [Related]
42. Salmeterol in children.
Br J Hosp Med; 1991 Nov; 46(5):344. PubMed ID: 1683591
[No Abstract] [Full Text] [Related]
43. Lessons from structure-function studies in asthma: myths and truths about what we teach.
Irvin CG
J Appl Physiol (1985); 2006 Jul; 101(1):7-9. PubMed ID: 16782831
[No Abstract] [Full Text] [Related]
44. Asthma specific quality of life scale in a study of salmeterol hydroxynaphthoate.
Hyland ME; Coward G; Upchurch F; Jones KP
Br J Gen Pract; 1991 May; 41(346):214-5. PubMed ID: 1678957
[No Abstract] [Full Text] [Related]
45. The pathobiologic implications for treatment. Old and new strategies in the treatment of chronic asthma.
Horiuchi T; Castro M
Clin Chest Med; 2000 Jun; 21(2):381-95, x. PubMed ID: 10907595
[TBL] [Abstract][Full Text] [Related]
46. [Can the management of patients with asthma be improved at present?].
Michel FB
Rev Mal Respir; 1992; 9 Suppl 1():R3-5. PubMed ID: 1350368
[TBL] [Abstract][Full Text] [Related]
47. [Effect of beta-adrenergic drugs on bronchial secretion].
Blasi A; Olivieri D; Marzo C
Minerva Med; 1976 Mar; 67(16):1049-54. PubMed ID: 4755
[No Abstract] [Full Text] [Related]
48. Salmeterol does not cause tolerance during long-term asthma therapy.
Arledge TE; Liddle R; Stahl E; Rossing TH
J Allergy Clin Immunol; 1996 Dec; 98(6 Pt 1):1116-9. PubMed ID: 8977514
[No Abstract] [Full Text] [Related]
49. Meeting the obligation to balance bioethics and clinical trial design in asthma.
Bleecker ER; Nelson HS; Kraft M; Corren J; Meyers DA; Yancey SW; Anderson WH; Emmett AH; Ortega HA
Am J Respir Crit Care Med; 2010 Apr; 181(7):648-50. PubMed ID: 20335380
[No Abstract] [Full Text] [Related]
50. [Variety of pharmacological action of beta agonists].
Takahashi S; Kokubu F; Adachi M
Arerugi; 1992 May; 41(5):557-62. PubMed ID: 1355646
[No Abstract] [Full Text] [Related]
51. Managing bronchospasm with short-acting beta(2)-agonists.
Fitzgerald MA
Nurse Pract; 2006 Sep; 31(9):47-53. PubMed ID: 16971833
[No Abstract] [Full Text] [Related]
52. Regulation of NO-producing function of the lungs with salmeterol.
Eliseeva EV; Romanova NA; Maistrovskaya YV
Bull Exp Biol Med; 2001 Jul; 132(1):709-12. PubMed ID: 11687859
[TBL] [Abstract][Full Text] [Related]
53. Long acting beta 2 agonists and the risk of life threatening asthma.
Ernst P
Thorax; 1998 Jan; 53(1):1-2. PubMed ID: 9577513
[No Abstract] [Full Text] [Related]
54. Genotyping and drug response: use of single nucleotide polymorphisms (SNPs) versus haplotypes to predict albuterol efficacy.
Schubbert S
AAPS PharmSci; 2001; 3(3):1. PubMed ID: 11783424
[No Abstract] [Full Text] [Related]
55. Contrasting properties of albuterol stereoisomers.
Page CP; Morley J
J Allergy Clin Immunol; 1999 Aug; 104(2 Pt 2):S31-41. PubMed ID: 10452786
[TBL] [Abstract][Full Text] [Related]
56. Salmeterol.
Johnson M
Med Res Rev; 1995 May; 15(3):225-57. PubMed ID: 7658751
[No Abstract] [Full Text] [Related]
57. Levalbuterol hydrochloride.
Slattery D; Wong SW; Colin AA
Pediatr Pulmonol; 2002 Feb; 33(2):151-7. PubMed ID: 11802253
[TBL] [Abstract][Full Text] [Related]
58. Question from the clinician: levalbuterol in managing pediatric asthma.
Abbott MB; Levin RH; Miller JA
Pediatr Rev; 2002 Nov; 23(11):401-3. PubMed ID: 12415020
[No Abstract] [Full Text] [Related]
59. Beta-mimetic agents and other bronchodilating drugs in children.
Geubelle F; Mossay C
Acta Paediatr Belg; 1979; 32(2):79-88. PubMed ID: 40386
[No Abstract] [Full Text] [Related]
60. [Beta-adrenergic agents in asthma].
Morales AM; Osuna LA; Javier RC; Suárez FN; Aldana IO
Rev Alerg Mex; 1996; 43(1):2-4. PubMed ID: 8901032
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
